Title:
マーカー分子に基づいて、アミロイド陽性認知症を罹患していると、または発症するリスクがあると個体を同定する方法、および関連する使用
Document Type and Number:
Japanese Patent JP7437376
Kind Code:
B2
Abstract:
The present disclosure relates to identifying an individual as having or being at risk of developing an amyloid-positive dementia based on marker molecules amyloid β40 (Aβ40), amyloid β42 (Aβ42) and total Tau (tTau), the use of the marker molecules for the identification of an individual having or being at risk of developing an amyloid-positive dementia and a method for detecting an individual with an increased value for the combination of the marker molecules.
Inventors:
Bitnell, Tobias
Carl, Johann
Rifke, Valeria
Stephen, Helena
Josham, Martina
Carl, Johann
Rifke, Valeria
Stephen, Helena
Josham, Martina
Application Number:
JP2021502867A
Publication Date:
February 22, 2024
Filing Date:
July 17, 2019
Export Citation:
Assignee:
Genentech, Incorporated
International Classes:
G01N33/53
Domestic Patent References:
| JP2015532592A | ||||
| JP2013527919A |
Foreign References:
| US20130164217 |
Other References:
TZEN Kai-Yuan et al.,Plasma Aβ but Not Tau is Related to Brain PiB Retention in Early Alzheimer’s Disease,ACS Chemical Neuroscience,2014年08月13日,Vol. 5, No. 9,p.830-836,DOI: 10.1021/cn500101j
MATTSSON Niklas et al.,Plasma tau in Alzheimer disease,Neurology,2016年09月30日,Vol. 87, No. 17,p.1827-1835,DOI: 10.1212/WNL.0000000000003246
ZETTERBERG Henrik et al.,Plasma tau levels in Alzheimer's disease,Alzheimer's Research & Therapy,2013年,Vol. 5, No. 2,p.9,DOI: 10.1186/alzrt163
NAKAMURA Akinori et al.,High performance plasma amyloid-β biomarkers for Alzheimer’s disease,Nature,2018年01月31日,Vol. 554, No. 7691,p.249-254,DOI: 10.1038/nature25456
MATTSSON Niklas et al.,Plasma tau in Alzheimer disease,Neurology,2016年09月30日,Vol. 87, No. 17,p.1827-1835,DOI: 10.1212/WNL.0000000000003246
ZETTERBERG Henrik et al.,Plasma tau levels in Alzheimer's disease,Alzheimer's Research & Therapy,2013年,Vol. 5, No. 2,p.9,DOI: 10.1186/alzrt163
NAKAMURA Akinori et al.,High performance plasma amyloid-β biomarkers for Alzheimer’s disease,Nature,2018年01月31日,Vol. 554, No. 7691,p.249-254,DOI: 10.1038/nature25456
Attorney, Agent or Firm:
Osamu Yamamoto
Toru Miyamae
Junichi Matsuo
Toru Miyamae
Junichi Matsuo